Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Phase II study shows oral tazarotene treatment yields QOL benefits for sufferers of severe acne
Washington D.C. ?? Patients with severe nodulocystic acne treated with oral tazarotene experience a substantial improvement in acne-specific health-related quality of life (HRQOL), according to the results of a Phase II dose-ranging study presented by Patricia S. Walker, M.D., Ph.D., at the annual meeting of the American Academy of Dermatology.
Related Videos
Related Content
